Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada.
Institute for Better Health, Trillium Health Partners, Mississauga, ON, Canada.
J Med Internet Res. 2023 Dec 28;25:e49173. doi: 10.2196/49173.
e-Prescribing is designed to assist in facilitating safe and appropriate prescriptions for patients. Currently, it is unknown to what extent e-prescribing for opioids influences experiences and outcomes. To address this gap, a rapid scoping review was conducted.
This rapid scoping review aims to (1) explore how e-prescribing has been used clinically; (2) examine the effects of e-prescribing on clinical outcomes, the patient or clinician experience, service delivery, and policy; and (3) identify current gaps in the present literature to inform future studies and recommendations.
A rapid scoping review was conducted following the guidance of the JBI 2020 scoping review methodology and the World Health Organization guide to rapid reviews. A comprehensive literature search was completed by an expert librarian from inception until November 16, 2022. Three databases were electronically searched: MEDLINE (Ovid), Embase (Ovid), and Scopus (Elsevier). The search criteria were as follows: (1) e-prescribing programs targeted to the use or misuse of opioids, including those that were complemented or accompanied by clinically focused initiatives, and (2) a primary research study of experimental, quasi-experimental, observational, qualitative, or mixed methods design. An additional criterion of an ambulatory component of e-prescribing (eg, e-prescribing occurred upon discharge from acute care) was added at the full-text stage. No language limitations or filters were applied. All articles were double screened by trained reviewers. Gray literature was manually searched by a single reviewer. Data were synthesized using a descriptive approach.
Upon completing screening, 34 articles met the inclusion criteria: 32 (94%) peer-reviewed studies and 2 (6%) gray literature documents (1 thesis study and 1 report). All 33 studies had a quantitative component, with most highlighting e-prescribing from acute care settings to community settings (n=12, 36%). Only 1 (3%) of the 34 articles provided evidence on e-prescribing in a primary care setting. Minimal prescriber, pharmacist, and clinical population characteristics were reported. The main outcomes identified were related to opioid prescribing rates, alerts (eg, adverse drug events and drug-drug interactions), the quantity and duration of opioid prescriptions, the adoption of e-prescribing technology, attitudes toward e-prescribing, and potential challenges with the implementation of e-prescribing into clinical practice. e-Prescribing, including key features such as alerts and dose order sets, may reduce prescribing errors.
This rapid scoping review highlights initial promising results with e-prescribing and opioid therapy management. It is important that future work explores the experience of prescribers, pharmacists, and patients using e-prescribing for opioid therapy management with an emphasis on prescribers in the community and primary care. Developing a common set of quality indicators for e-prescribing of opioids will help build a stronger evidence base. Understanding implementation considerations will be of importance as the technology is integrated into clinical practice and health systems.
电子处方旨在帮助为患者开具安全且适当的处方。目前,尚不清楚电子开处方对阿片类药物的影响程度。为了弥补这一空白,进行了快速范围界定审查。
本快速范围界定审查旨在:(1) 探讨电子处方在临床上的使用情况;(2) 研究电子处方对临床结果、患者或临床医生体验、服务提供和政策的影响;(3) 确定当前文献中的空白,以为未来的研究和建议提供信息。
按照 JBI 2020 范围界定审查方法和世界卫生组织快速审查指南的指导进行快速范围界定审查。一位专家图书管理员从开始到 2022 年 11 月 16 日完成了全面的文献检索。通过电子方式在三个数据库中进行了搜索:MEDLINE(Ovid)、Embase(Ovid)和 Scopus(Elsevier)。搜索标准如下:(1) 针对阿片类药物的使用或滥用的电子处方计划,包括那些与临床重点举措相补充或伴随的计划,以及 (2) 对实验、准实验、观察性、定性或混合方法设计的主要研究。在全文筛选阶段增加了电子处方的门诊部分(例如,电子处方是在急性护理出院时开出的)的附加标准。未应用语言限制或筛选器。所有文章均由经过培训的审查员进行双盲筛选。通过描述性方法对数据进行综合。
完成筛选后,有 34 篇文章符合纳入标准:32 篇(94%)同行评议研究和 2 篇(6%)灰色文献(1 篇论文研究和 1 篇报告)。所有 33 项研究均具有定量组成部分,其中大多数突出了从急性护理环境向社区环境开具电子处方的情况(n=12,36%)。只有 1 篇(3%)文章提供了初级保健环境中电子处方的证据。报道了最小的开处方者、药剂师和临床人群特征。确定的主要结果与阿片类药物的开具率、警报(例如,药物不良事件和药物相互作用)、阿片类药物的开具量和持续时间、电子处方技术的采用、对电子处方的态度以及电子处方在临床实践中的实施所面临的潜在挑战有关。电子处方,包括警报和剂量医嘱集等关键功能,可能会减少处方错误。
本快速范围界定审查突出了电子处方和阿片类药物治疗管理方面的初步可喜结果。重要的是,未来的工作应探讨开处方者、药剂师和使用电子处方治疗管理阿片类药物的患者的体验,重点关注社区和初级保健中的开处方者。制定一套针对阿片类药物电子处方的共同质量指标将有助于建立更强大的证据基础。了解实施方面的问题将对将该技术纳入临床实践和卫生系统非常重要。